牛熊異動 | 新產品上市,港交牛證漲超100%
港交所(00388.HK)升逾3%,股價再創歷史新高,今年以來累計升幅約55%。相關衍生品港交法興一二牛L(69081)升超100%。
繼實施“滬深港通”及“債券通”後,互聯互通機制進一步延伸至ETF終於傳來突破。中港兩地證監會於上週五(28日)宣佈,香港及深圳各自認可2只ETF以“ETF互掛計劃”上市。產品由境內基金管理人在境內設立,採取合格境內機構投資者(QDII)模式,將不低於90%的基金淨資產投資於香港單隻目標ETF,跟蹤恆生中國企業指數、標普新中國行業(A股上限)指數市場表現,基金份額在深圳證券交易所上市交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.